Skip to content

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

JMCP

Read the full article
Authors

Scott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, Justin T Puckett, Nnadozie Emechebe, Arliene Ravelo, Sachin Kamal-Bahl, Jalpa A Doshi